Ayman Al‐Shurbaji

1.4k total citations
32 papers, 1.0k citations indexed

About

Ayman Al‐Shurbaji is a scholar working on Pharmacology, Pulmonary and Respiratory Medicine and Biochemistry. According to data from OpenAlex, Ayman Al‐Shurbaji has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Biochemistry. Recurrent topics in Ayman Al‐Shurbaji's work include Pharmacogenetics and Drug Metabolism (9 papers), Potassium and Related Disorders (8 papers) and Membrane-based Ion Separation Techniques (6 papers). Ayman Al‐Shurbaji is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Potassium and Related Disorders (8 papers) and Membrane-based Ion Separation Techniques (6 papers). Ayman Al‐Shurbaji collaborates with scholars based in Sweden, United States and United Kingdom. Ayman Al‐Shurbaji's co-authors include Marja­‐Liisa Dahl, Per Dalén, Leif Bertilsson, Lars Berglund, Daniel K. Asiedu, Jon Skorve, Rolf K. Berge, Bruce Spinowitz, Ingemar Björkhem and Vera Lisovskaja and has published in prestigious journals such as Circulation, Kidney International and Journal of the American Society of Nephrology.

In The Last Decade

Ayman Al‐Shurbaji

30 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ayman Al‐Shurbaji Sweden 14 344 289 187 155 149 32 1.0k
G. G. Belz Germany 26 123 0.4× 452 1.6× 258 1.4× 96 0.6× 72 0.5× 116 2.1k
Tomonori Tateishi Japan 23 545 1.6× 244 0.8× 66 0.4× 67 0.4× 62 0.4× 80 1.5k
Gladys R. Rios United States 15 771 2.2× 511 1.8× 164 0.9× 58 0.4× 65 0.4× 28 1.7k
S. Cholerton United Kingdom 24 937 2.7× 716 2.5× 88 0.5× 117 0.8× 118 0.8× 40 2.1k
P Lettéron France 20 520 1.5× 419 1.4× 86 0.5× 96 0.6× 89 0.6× 30 1.4k
Kevin Moore United Kingdom 14 190 0.6× 233 0.8× 172 0.9× 60 0.4× 69 0.5× 23 1.9k
Hong‐Guang Xie China 20 612 1.8× 402 1.4× 73 0.4× 114 0.7× 36 0.2× 63 1.6k
Julie Ducharme Canada 20 341 1.0× 323 1.1× 55 0.3× 44 0.3× 35 0.2× 45 1.3k
Philippe Coassolo Switzerland 20 577 1.7× 271 0.9× 83 0.4× 40 0.3× 30 0.2× 45 1.4k
Orhan Canbolat Türkiye 19 88 0.3× 329 1.1× 66 0.4× 127 0.8× 179 1.2× 39 1.2k

Countries citing papers authored by Ayman Al‐Shurbaji

Since Specialization
Citations

This map shows the geographic impact of Ayman Al‐Shurbaji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayman Al‐Shurbaji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayman Al‐Shurbaji more than expected).

Fields of papers citing papers by Ayman Al‐Shurbaji

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayman Al‐Shurbaji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayman Al‐Shurbaji. The network helps show where Ayman Al‐Shurbaji may publish in the future.

Co-authorship network of co-authors of Ayman Al‐Shurbaji

This figure shows the co-authorship network connecting the top 25 collaborators of Ayman Al‐Shurbaji. A scholar is included among the top collaborators of Ayman Al‐Shurbaji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ayman Al‐Shurbaji. Ayman Al‐Shurbaji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fishbane, Steven, Laura M. Dember, Michel Jadoul, et al.. (2025). The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis. Kidney International. 108(4). 686–694.
2.
3.
Tardif, Jean‐Claude, Jean L. Rouleau, Glenn M. Chertow, et al.. (2022). Potassium Reduction with Sodium Zirconium Cyclosilicate in Patients with Heart Failure. ESC Heart Failure. 10(2). 1066–1076. 22 indexed citations
4.
Fishbane, Steven, Martin L. Ford, Masafumi Fukagawa, et al.. (2022). Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE. BMC Nephrology. 23(1). 59–59. 7 indexed citations
5.
6.
Fishbane, Steven, Martin L. Ford, Masafumi Fukagawa, et al.. (2022). Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients. Kidney International Reports. 7(4). 908–912.
7.
8.
Roger, Simon D., Bruce Spinowitz, Edgar V. Lerma, et al.. (2019). Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE. American Journal of Nephrology. 50(6). 473–480. 54 indexed citations
9.
Berninger, Erik, Gunnar Alván, Kjell Karlsson, et al.. (2006). The effect of intravenously administered mexiletine on tinnitus-a pilot study. International Journal of Audiology. 45(12). 689–696. 3 indexed citations
10.
Lindh, Jonatan D., Anita Annas, Lennart Meurling, Marja­‐Liisa Dahl, & Ayman Al‐Shurbaji. (2003). Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. European Journal of Clinical Pharmacology. 59(5-6). 401–406. 33 indexed citations
11.
Annas, Anita, Kjell Carlström, Gunnar Alván, & Ayman Al‐Shurbaji. (2003). The effect of ketoconazole and diltiazem on oestrogen metabolism in postmenopausal women after single dose oestradiol treatment. British Journal of Clinical Pharmacology. 56(3). 334–336. 1 indexed citations
12.
Al‐Shurbaji, Ayman & Juliette Säwe. (2002). The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype. European Journal of Clinical Pharmacology. 57(12). 877–881. 4 indexed citations
13.
Al‐Shurbaji, Ayman & L. Tokics. (2002). The pharmacokinetics of ketobemidone in critically ill patients. British Journal of Clinical Pharmacology. 54(6). 583–586. 4 indexed citations
14.
Svensson, Jan‐Olof, Juliette Säwe, & Ayman Al‐Shurbaji. (2001). Determination of Ketobemidone and Its Metabolites in Plasma and Urine Using Solid-Phase Extraction and Liquid Chromatography-Mass Spectrometry. Therapeutic Drug Monitoring. 23(4). 399–405. 7 indexed citations
15.
Al‐Shurbaji, Ayman, et al.. (2001). Quantitative Pharmacogenetics of Nortriptyline. Clinical Pharmacokinetics. 40(11). 869–877. 21 indexed citations
16.
Hassan, Moustapha, Jan‐Olof Svensson, Christína Nilsson, et al.. (2000). Ketobemidone May Alter Busulfan Pharmacokinetics During High-Dose Therapy. Therapeutic Drug Monitoring. 22(4). 383–385. 16 indexed citations
17.
Asiedu, Daniel K., Ayman Al‐Shurbaji, Arild C. Rustan, et al.. (1995). Hepatic Fatty Acid Metabolism as a Determinant of Plasma and Liver Triacylglycerol Levels. Studies on Tetradecylthioacetic and Tetradecylthiopropionic Acids. European Journal of Biochemistry. 227(3). 715–722. 35 indexed citations
18.
Asiedu, Daniel K., Ayman Al‐Shurbaji, Arild C. Rustan, et al.. (1995). Hepatic Fatty Acid Metabolism as a Determinant of Plasma and Liver Triacylglycerol Levels. European Journal of Biochemistry. 227(3). 715–722. 17 indexed citations
19.
Al‐Shurbaji, Ayman, et al.. (1994). Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: Effect of HMG-CoA reductase inhibitors. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1214(1). 32–38. 10 indexed citations
20.
Al‐Shurbaji, Ayman, Lars Berglund, J. Thonstad, et al.. (1989). Rat Adipose Tissue Phosphatidic Acid Phosphatase: Lack of Effect of Nucleotides on Cytosolic Enzyme Activity.. Acta chemica Scandinavica/Acta chemica Scandinavica. B, Organic chemistry and biochemistry/Acta chemica Scandinavica. A, Physical and inorganic chemistry/Acta chemica Scandinavica. Series B. Organic chemistry and biochemistry/Acta chemica Scandinavica. Series A, Physical and inorganic chemistry. 43(7). 680–683. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. G. Belz Breakdown of academic impact, for papers by Tomonori Tateishi Breakdown of academic impact, for papers by Gladys R. Rios Breakdown of academic impact, for papers by S. Cholerton Breakdown of academic impact, for papers by P Lettéron Breakdown of academic impact, for papers by Kevin Moore Breakdown of academic impact, for papers by Hong‐Guang Xie Breakdown of academic impact, for papers by Julie Ducharme Breakdown of academic impact, for papers by Philippe Coassolo Breakdown of academic impact, for papers by Orhan Canbolat
Rankless by CCL
2026